Clinical trials: Psychotic Disorder
Schizophrenia
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
The purpose of this 6 month study is to compare the metabolic effects of paliperidone ER and olanzapine in patients with schizophrenia, using the ratio of the concentration of lipids (triglycerides (TG)) in the blood to the…
- Trial name
- NCT00645099
- Testing
- olanzapine, paliperidone ER
- Where
- 46 sites in Argentina, Egypt and 12 more
- Volunteers
- 462 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
- Trial name
- NCT04158687
- Testing
- CTP-692
- Where
- 26 sites in United States
- Volunteers
- 326 people
- Sponsor
- Concert Pharmaceuticals
Schizophrenia
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.
- Trial name
- NCT01892384
- Testing
- BI 409306
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Intranasal Insulin Treatment in Patients With Schizophrenia
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on…
- Trial name
- NCT00575666
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Massachusetts, Worcester
Cigarette Smoking, Schizophrenia
Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness
The overall aim of this study is to test the effect of academic detailing (i.e. provider-level educational intervention focused on evidence-based smoking cessation treatment for those with psychiatric illness) and community…
- Conditions
- Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major
- Trial name
- NCT02845440
- Testing
- Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 1,165 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured positron emission tomography (PET) imaging .
- Trial name
- NCT04038957
- Testing
- SEP-363856
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
Purpose: The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Overweight
- Trial name
- MELT (NCT02796144)
- Testing
- Lorcaserin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy of low-dose LEV in reducing hippocampal activity in schizophrenia.
- Trial name
- NCT02647437
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Safety and Tolerability Study of Drug to Treat Schizophrenia
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
- Trial name
- NCT00044005
- Testing
- Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
- Where
- 26 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Study of Cognitive Adaptation Training in Inpatient Forensic Environments
The proposed project will be a mixed-methods feasibility study of modified Cognitive Adaptation Training for an inpatient forensic mental health population (finCAT).
- Trial name
- finCAT (NCT04294719)
- Testing
- Cognitive Adaptation Training (CAT)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to…
- Trial name
- DMXB-A (NCT00100165)
- Testing
- 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
Physical Disability, Chronic Mental Disorder
Persons With Disabilities Generating Quality Metrics
No standard way exists to measure the quality of medical care or independent living long-term services and supports provided to persons with disabilities.
- Trial name
- NCT02390557
- Testing
- Survey, YESHealth
- Volunteers
- 451 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophrenia-related Psychotic Disorder
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six…
- Trial name
- NCT02006628
- Testing
- GWP42003
- Where
- 14 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Jazz Pharmaceuticals
Schizophrenia, Cigarette Smoking
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with…
- Trial name
- NCT00802919
- Testing
- Varenicline
- Where
- 4 sites in United States, China and 1 more
- Volunteers
- 93 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metabolic Complications
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
- Trial name
- NCT00682448
- Testing
- Metformin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rush University Medical Center
Schizophrenia
Confirmatory Study of DSP-5423P in Patients With Schizophrenia
The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.
- Trial name
- NCT02287584
- Testing
- DSP-5423P 40mg, DSP-5423P 80mg, DSP-5423P Active-to-Flex
- Where
- 8 sites in China, Japan and 6 more
- Volunteers
- 580 people
- Sponsor
- Sumitomo Pharma Co., Ltd.